Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:10286
Name prostate carcinoma
Definition A prostate cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Dactolisib prostate carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01385228 Phase I Docetaxel + Pazopanib + Pegfilgrastim Pazopanib, Docetaxel, Prednisone Prostate Completed
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed
NCT01561482 Phase II Metformin + Simvastatin Study of Metformin With Simvastatin for Men With Prostate Carcinoma Withdrawn
NCT02113657 Phase II Ipilimumab T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Completed
NCT02234115 Phase III Leuprolide Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma Completed
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Recruiting
NCT02552394 Phase I J591 J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts Recruiting
NCT02565901 Phase Ib/II Carboplatin + Docetaxel + Sirolimus Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Terminated
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT02952534 Phase II Rucaparib A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) Active, not recruiting
NCT02975934 Phase III Rucaparib Docetaxel Enzalutamide Abiraterone A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) Recruiting
NCT03261999 Phase III Leuprolide Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Completed
NCT03263650 Phase II Cabazitaxel + Carboplatin Olaparib Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Recruiting
NCT03837353 Phase Ib/II DKN-01 DKN-01 + Docetaxel A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 Recruiting
NCT04179396 Phase I Enzalutamide + Rucaparib Abiraterone + Rucaparib Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP) Recruiting
NCT04388852 Phase I DS-3201b + Ipilimumab DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Not yet recruiting